The role of microglia in the translational 5xFAD wildling mouse model of Alzheimer's disease

Microglia are important for brain function and play a very important role in Alzheimer's disease (AD). In AD toxic beta-amyloid (Aβ) depositions accumulate in the brain. As a result, nerve cells die in the course of the disease and certain brain functions such as orientation and memory are increasingly impaired. Microglia remove Aβ deposits in order to protect the nerve cells. In previous studies, the applicant found that microglia are significantly influenced by certain bacterial molecules.

Clinical translation of next-generation imaging biomarkers using artificial intelligence

In modern medicine, and especially in the field of radiological imaging, huge quantities of data are produced – so much that medical diagnosis of the images poses an increasingly time- and labor-intensive challenge. The utilization of artificial intelligence (AI) promises a major potential here in achieving synergetic effects: Activities that are carried out best by AI algorithms can be combined with those best suited for medical professionals.

Function and interaction between the blood-brain barrier and neuronal excitability as therapeutic strategies in the case of cerebral ischemia and central autoimmunity

The demise of neuronal cells causes disabilities in the case of multiple sclerosis (MS) and a stroke. Jun.-Prof. Dr. Timo Uphaus researches the molecular causes of neuronal cell death in the course of these diseases. The focus thereby lies on the blood-brain barrier and its significance for the functioning of neural connections along with the influence of neuronal excitability on their survival. From the knowledge gained from these findings, “neuroprotective” therapy approaches are developed whose effectiveness will be tested in randomized clinical studies.

New systems biology approaches toward studying kidney diseases

Chronic kidney diseases that develop above all in the course of elevated blood pressure and elevated blood sugar levels pose an increasing problem for healthcare systems worldwide. In the project funded by EKFS, PD Dr. Christoph Kuppe and his team research new pathophysiological bases regarding disease mechanisms in chronic renal diseases. The goal is the development of new therapies using new, patient-centered methods. In the first step, a “map” of regulatory gene changes is drawn up for each kidney cell to obtain a better understanding of pathophysiological alterations.

Nachgefragt: Was macht eigentlich Dr. Carolin Lerchenmüller, Erst- und Zweitantragstellerin aus dem Jahr 2019?

Dr. Carolin Lerchenmüller ist Mutter von drei Kindern und sitzt der Projektgruppe Frauen und Familie in der Kardiologie der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. vor. Nach ihrem Medizinstudium realisierte sie zügig, dass ihre Leidenschaft für die Grundlagenwissenschaft parallel zum klinischen Alltag schwer aufrechtzuerhalten ist. Sie entschied sich zunächst, als Postdoktorandin im Labor von Anthony Rosenzweig am Massachusetts General Hospital der Harvard Medical School zu forschen.

Else Kröner reentry funding for researching physicians following family-pause phase

Bad Homburg v.d. Höhe, March 1, 2023 – Parental leave, childcare or caregiving for relatives: For medical doctors who have utilized a longer period of time for their families or caregiving, the return to the preceding career is often extremely difficult. For the first time, the foundation Else Kröner-Fresenius-Stiftung (EKFS) is therefore announcing flexible and individually deployable funding resources up to 400,000 euros – respectively applicable in each case for an effective reentry and the continuation of a successful career.

Targeting a Common Checkpoint of Brain Disease by novel Autotaxin inhibitors

Project partner:

Prof. Dr. med. Johannes Vogt, Direktor des Instituts für Neuroanatomie der Universität Köln, Prof. Dr. med. Timo Uphaus, EKFS-Tanslations-Professur an der Klinik für Neurologie der Universitätsmedizin Mainz, Prof. Dr. med. Dr. phil. Dipl.-Psych. Udo Dannlowski, Direktor des Instituts für Translationale Psychiatrie, Universitätsklinikum Münster
 

Subscribe to Scientific Funding